Casdin Partners Master Fund, L Purchases 4,820,959 Shares of Standard BioTools Inc. (NASDAQ:LAB) Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 4,820,959 shares of Standard BioTools stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average price of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Standard BioTools Trading Up 13.2 %

Shares of NASDAQ:LAB opened at $1.20 on Thursday. The company has a 50-day moving average price of $1.56 and a 200-day moving average price of $1.79. The company has a market cap of $446.71 million, a price-to-earnings ratio of -1.69 and a beta of 1.57. Standard BioTools Inc. has a 12 month low of $0.99 and a 12 month high of $3.04.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of Standard BioTools by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 6,975,221 shares of the company’s stock worth $12,209,000 after buying an additional 25,504 shares during the last quarter. Hollow Brook Wealth Management LLC purchased a new stake in Standard BioTools in the third quarter worth $10,679,000. State Street Corp boosted its holdings in Standard BioTools by 26.7% in the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after acquiring an additional 1,157,984 shares in the last quarter. Barclays PLC increased its position in Standard BioTools by 13.2% during the 3rd quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after purchasing an additional 377,195 shares during the period. Finally, Mirabella Financial Services LLP bought a new position in Standard BioTools in the 4th quarter worth $5,478,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analysts Set New Price Targets

Separately, KeyCorp lowered Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.